Company insight
Innovative delivery of biologics
Global partner for drug packaging and drug delivery Gerresheimer introduces the innovative SensAIR platform, the first of its kind in drug delivery devices for biologics.
drugs of higher viscosity, such as monoclonal antibodies (mAb). The aim is to provide patients with the best possible support in the subcutaneous delivery of large-volume biologics. The ready-to-use SensAIR on-body delivery device is easy to use and enables patients to start medication in a self-determined manner in familiar surroundings, for example at home.
G
SensAIR can be adapted to drugs and biologics of different viscosities and other requirements. This applies to the needle used, cartridge sizes and possible connectivity – for example to the patient’s smartphone. Together with Gerresheimer’s one-stop shop quality promise – which includes a solution from the cartridge to the drug delivery device from one single source – SensAIR enables optimised delivery of biologics.
“Everyone benefits from SensAIR: patients, caregivers and also doctors. This device is an innovative medical device which, when worn on the body, delivers up to 20ml of biologics subcutaneously to the patient,” says Oliver Haferbeck, head of the advanced technology and innovation unit at Gerresheimer and CEO of Sensile- Medical. He explains that patients gain significant quality of life because they can administer their own medication at home. The easy-to-use concept ensures that the patient does not have to carry out any lengthy and complicated preparation steps but can operate the device easily. The technology, function, design and construction of the platform were developed by Gerresheimer experts, and the product is supplied from one single source.
Patient quality of life To date, many patients with a wide variety of diseases have to endure long and
16
erresheimer, with SensAIR, presents a platform for on-body drug delivery that can administer
stressful infusions in a hospital setting to treat their condition. How much more straightforward would it be if patients could carry out the treatment at home? SensAIR
makes life easier for these patients, as they can care for themselves over a longer period of time and – depending on the disease – only need to visit a doctor or hospital for check-ups. SensAIR is an innovative product platform for the administration of large-volume biologics of different viscosities.
A simple concept
The SensAIR drug delivery device is characterised by a simple concept that can be cost-effectively adapted to different requirements, especially patient needs. Gerresheimer thus offers a platform solution, which provides a wide range of options for the biologic to be applied, including an appropriate delivery time of the total volume to be injected from glass cartridges up to 10ml and up to 20ml, as well as connectivity. With this focus, SensAIR is attractive to the market even with varying quantities of devices per year, as existing developments and processes can be adapted in the shortest possible time. The existing technologies and know-how, which have already proven themselves in the market, are consistently applied in SensAIR. This presents a significant advantage in terms of time to market, by quickly enabling clinical trials.
Gerresheimer is therefore a one-stop shop for the industry and covers the whole value chain of design, development and manufacturing of primary packaging and
With SensAIR, Gerresheimer presents a new platform for on-body drug delivery that can administer drugs of higher viscosity, such as monoclonal antibodies (mAb), in precise doses.
devices. This represents
significant added value as a long-term partner and system supplier.
Health is wealth
Gerresheimer is the global partner for companies in pharma, medical pharmaceuticals, biotech, healthcare and cosmetics with a very broad product range in packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the final product. It achieves its ambitious goals through a high level of innovation power, industrial competence and concentration on quality and customer focus.
In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and manufacturing centres in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4bn. With its products and solutions, Gerresheimer plays an essential role in people’s health and wellbeing. ●
www.gerresheimer.com World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65
